NASDAQ:IMCR

Immunocore Competitors

$40.31
+0.63 (+1.59 %)
(As of 05/7/2021 12:00 AM ET)
Add
Compare
Today's Range
$39.16
$40.91
50-Day Range
$32.22
$46.20
52-Week Range
$30.92
$61.99
Volume25,320 shs
Average Volume105,724 shs
Market Capitalization$1.74 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Immunocore (NASDAQ:IMCR) Vs. ABCM, RXRX, SANA, SEER, NUVB, and IBRX

Should you be buying IMCR stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to Immunocore, including Abcam (ABCM), Recursion Pharmaceuticals (RXRX), Sana Biotechnology (SANA), Seer (SEER), Nuvation Bio (NUVB), and ImmunityBio (IBRX).

Abcam (NASDAQ:ABCM) and Immunocore (NASDAQ:IMCR) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, risk, profitability, analyst recommendations and institutional ownership.

Profitability

This table compares Abcam and Immunocore's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AbcamN/AN/AN/A
ImmunocoreN/AN/AN/A

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Abcam and Immunocore, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Abcam04302.43
Immunocore01202.67

Abcam currently has a consensus price target of $22.00, indicating a potential upside of 3.48%. Immunocore has a consensus price target of $54.3333, indicating a potential upside of 34.79%. Given Immunocore's stronger consensus rating and higher probable upside, analysts plainly believe Immunocore is more favorable than Abcam.

Valuation & Earnings

This table compares Abcam and Immunocore's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AbcamN/AN/AN/AN/AN/A
ImmunocoreN/AN/AN/AN/AN/A

Summary

Immunocore beats Abcam on 2 of the 3 factors compared between the two stocks.

Immunocore (NASDAQ:IMCR) and Recursion Pharmaceuticals (NASDAQ:RXRX) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, profitability, risk, dividends, earnings and institutional ownership.

Valuation and Earnings

This table compares Immunocore and Recursion Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ImmunocoreN/AN/AN/AN/AN/A
Recursion PharmaceuticalsN/AN/AN/AN/AN/A

Profitability

This table compares Immunocore and Recursion Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ImmunocoreN/AN/AN/A
Recursion PharmaceuticalsN/AN/AN/A

Analyst Recommendations

This is a summary of current ratings and target prices for Immunocore and Recursion Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Immunocore01202.67
Recursion Pharmaceuticals0000N/A

Immunocore currently has a consensus target price of $54.3333, suggesting a potential upside of 34.79%. Given Immunocore's higher possible upside, equities analysts plainly believe Immunocore is more favorable than Recursion Pharmaceuticals.

Summary

Immunocore beats Recursion Pharmaceuticals on 2 of the 2 factors compared between the two stocks.

Sana Biotechnology (NASDAQ:SANA) and Immunocore (NASDAQ:IMCR) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, profitability, institutional ownership and valuation.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Sana Biotechnology and Immunocore, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sana Biotechnology02202.50
Immunocore01202.67

Sana Biotechnology currently has a consensus price target of $40.00, suggesting a potential upside of 120.14%. Immunocore has a consensus price target of $54.3333, suggesting a potential upside of 34.79%. Given Sana Biotechnology's higher possible upside, analysts plainly believe Sana Biotechnology is more favorable than Immunocore.

Valuation & Earnings

This table compares Sana Biotechnology and Immunocore's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sana BiotechnologyN/AN/AN/AN/AN/A
ImmunocoreN/AN/AN/AN/AN/A

Profitability

This table compares Sana Biotechnology and Immunocore's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Sana BiotechnologyN/AN/AN/A
ImmunocoreN/AN/AN/A

Immunocore (NASDAQ:IMCR) and Seer (NASDAQ:SEER) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, earnings, valuation, profitability, dividends and institutional ownership.

Analyst Recommendations

This is a breakdown of recent recommendations for Immunocore and Seer, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Immunocore01202.67
Seer02202.50

Immunocore currently has a consensus price target of $54.3333, suggesting a potential upside of 34.79%. Seer has a consensus price target of $68.00, suggesting a potential upside of 78.57%. Given Seer's higher possible upside, analysts clearly believe Seer is more favorable than Immunocore.

Valuation and Earnings

This table compares Immunocore and Seer's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ImmunocoreN/AN/AN/AN/AN/A
SeerN/AN/AN/AN/AN/A

Profitability

This table compares Immunocore and Seer's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ImmunocoreN/AN/AN/A
SeerN/AN/AN/A

Immunocore (NASDAQ:IMCR) and Nuvation Bio (NYSE:NUVB) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, earnings, valuation, profitability, dividends and institutional ownership.

Analyst Recommendations

This is a breakdown of recent recommendations for Immunocore and Nuvation Bio, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Immunocore01202.67
Nuvation Bio00603.00

Immunocore currently has a consensus price target of $54.3333, suggesting a potential upside of 34.79%. Nuvation Bio has a consensus price target of $17.40, suggesting a potential upside of 74.00%. Given Nuvation Bio's stronger consensus rating and higher possible upside, analysts clearly believe Nuvation Bio is more favorable than Immunocore.

Valuation and Earnings

This table compares Immunocore and Nuvation Bio's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ImmunocoreN/AN/AN/AN/AN/A
Nuvation BioN/AN/AN/AN/AN/A

Profitability

This table compares Immunocore and Nuvation Bio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ImmunocoreN/AN/AN/A
Nuvation BioN/AN/AN/A

Summary

Nuvation Bio beats Immunocore on 3 of the 3 factors compared between the two stocks.

Immunocore (NASDAQ:IMCR) and ImmunityBio (NASDAQ:IBRX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, earnings, valuation, profitability, dividends and institutional ownership.

Analyst Recommendations

This is a breakdown of recent recommendations for Immunocore and ImmunityBio, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Immunocore01202.67
ImmunityBio00103.00

Immunocore currently has a consensus price target of $54.3333, suggesting a potential upside of 34.79%. ImmunityBio has a consensus price target of $25.00, suggesting a potential upside of 49.34%. Given ImmunityBio's stronger consensus rating and higher possible upside, analysts clearly believe ImmunityBio is more favorable than Immunocore.

Valuation and Earnings

This table compares Immunocore and ImmunityBio's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ImmunocoreN/AN/AN/AN/AN/A
ImmunityBioN/AN/AN/AN/AN/A

Profitability

This table compares Immunocore and ImmunityBio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ImmunocoreN/AN/AN/A
ImmunityBioN/AN/AN/A

Summary

ImmunityBio beats Immunocore on 2 of the 3 factors compared between the two stocks.


Immunocore Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Abcam logo
ABCM
Abcam
1.1$21.26+2.4%$4.82 billionN/A0.00Gap Down
RXRX
Recursion Pharmaceuticals
0.0$27.73+1.0%$4.50 billionN/A0.00Gap Up
Sana Biotechnology logo
SANA
Sana Biotechnology
1.2$18.17+8.4%$3.41 billionN/A0.00Gap Down
SEER
Seer
1.2$38.08+5.6%$2.32 billionN/A0.00Upcoming Earnings
Gap Up
Nuvation Bio logo
NUVB
Nuvation Bio
2.2$10.00+0.0%$2.18 billionN/A0.00
IBRX
ImmunityBio
1.7$16.74+4.4%$1.83 billionN/A0.00Upcoming Earnings
Gap Down
BioAtla logo
BCAB
BioAtla
1.7$46.81+2.8%$1.58 billionN/A0.00Analyst Report
Gap Down
EWTX
Edgewise Therapeutics
1.6$29.24+0.2%$1.39 billionN/A0.00Quiet Period Expiration
Cullinan Oncology logo
CGEM
Cullinan Oncology
1.4$29.86+2.9%$1.30 billionN/A0.00Gap Down
Nurix Therapeutics logo
NRIX
Nurix Therapeutics
2.0$26.94+1.6%$1.19 billionN/A0.00Analyst Report
KNTE
Kinnate Biopharma
1.7$24.68+3.6%$1.07 billionN/A0.00Analyst Revision
News Coverage
Gap Down
Silverback Therapeutics logo
SBTX
Silverback Therapeutics
1.7$28.16+0.5%$982.87 millionN/A0.00
STEM
Stem
0.0$20.04+3.9%$960.88 millionN/A0.00News Coverage
Gap Up
Vor Biopharma logo
VOR
Vor Biopharma
1.9$24.53+3.6%$910.75 millionN/A0.00Analyst Downgrade
News Coverage
CNTB
Connect Biopharma
1.7$15.53+3.7%$893.04 millionN/A0.00Gap Up
FDMT
4D Molecular Therapeutics
1.3$32.80+2.4%$875.56 millionN/A0.00Gap Up
Pharming Group logo
PHAR
Pharming Group
0.0$13.20+4.5%$846.50 millionN/A0.00
Bolt Biotherapeutics logo
BOLT
Bolt Biotherapeutics
1.6$22.85+2.3%$830.10 millionN/A0.00Gap Up
iTeos Therapeutics logo
ITOS
iTeos Therapeutics
1.9$23.10+3.8%$810.79 millionN/A0.00Upcoming Earnings
Analyst Report
Gap Up
Gracell Biotechnologies logo
GRCL
Gracell Biotechnologies
1.4$11.50+0.0%$772.95 millionN/A0.00Analyst Upgrade
Pharvaris B.V. logo
PHVS
Pharvaris B.V.
1.5$22.63+7.6%$720.54 millionN/A0.00News Coverage
Gap Up
FNCH
Finch Therapeutics Group
2.0$12.66+2.1%$596.86 millionN/A0.00Gap Up
ACHL
Achilles Therapeutics plc American Depositary Shares
1.6$14.17+0.8%$575.61 millionN/A0.00Quiet Period Expiration
Gap Up
Inventiva logo
IVA
Inventiva
1.4$14.40+0.1%$556.27 millionN/A0.00Analyst Report
Gemini Therapeutics logo
GMTX
Gemini Therapeutics
1.7$11.98+0.2%$515.13 millionN/A0.00
BMEA
Biomea Fusion
0.0$16.94+0.8%$487.33 millionN/A0.00
MIGI
Mawson Infrastructure Group
0.0$1.05+5.7%$481.46 millionN/A0.00Gap Down
RAIN
Rain Therapeutics
1.3$18.39+9.4%$477.57 millionN/A0.00Gap Down
VECT
VectivBio
1.5$13.50+1.9%$459.20 millionN/A0.00Analyst Report
Analyst Revision
NexImmune logo
NEXI
NexImmune
2.0$19.59+1.1%$445.83 millionN/A0.00Analyst Revision
News Coverage
Angion Biomedica logo
ANGN
Angion Biomedica
1.6$14.24+0.6%$419.85 millionN/A0.00
Landos Biopharma logo
LABP
Landos Biopharma
1.8$10.46+3.5%$419.63 millionN/A0.00News Coverage
Gap Up
SGTX
Sigilon Therapeutics
1.4$13.30+1.8%$419.34 millionN/A0.00News Coverage
Terns Pharmaceuticals logo
TERN
Terns Pharmaceuticals
2.0$16.62+3.4%$417.58 millionN/A0.00News Coverage
Gap Down
Sensei Biotherapeutics logo
SNSE
Sensei Biotherapeutics
2.0$11.86+0.5%$362.77 millionN/A0.00News Coverage
Gap Down
RPHM
Reneo Pharmaceuticals
2.0$14.93+0.6%$361.47 millionN/A0.00Analyst Report
Analyst Revision
News Coverage
PRTG
Portage Biotech
0.0$27.97+1.1%$337.96 millionN/A0.00
Kaleido Biosciences logo
KLDO
Kaleido Biosciences
1.8$7.46+2.3%$317.19 millionN/A-2.95Earnings Announcement
IMPL
Impel NeuroPharma
0.3$15.03+0.3%$291.81 millionN/A0.00
Unity Biotechnology logo
UBX
Unity Biotechnology
1.1$4.63+2.8%$253.67 millionN/A-2.46Analyst Revision
News Coverage
Gap Down
VINC
Vincerx Pharma
1.0$15.75+6.8%$220.25 millionN/A0.00Gap Down
Decibel Therapeutics logo
DBTX
Decibel Therapeutics
2.2$7.90+6.1%$196.73 millionN/A0.00Gap Down
LBPH
Longboard Pharmaceuticals
1.9$9.97+6.9%$168.66 millionN/A0.00Analyst Revision
News Coverage
Gap Down
Annovis Bio logo
ANVS
Annovis Bio
0.0$23.47+6.6%$163.05 millionN/A0.00Upcoming Earnings
Gap Down
ImmunoPrecise Antibodies logo
IPA
ImmunoPrecise Antibodies
0.0$7.72+1.8%$147.99 millionN/A0.00
EVAX
Evaxion Biotech A/S
1.7$6.63+0.8%$127.29 millionN/A0.00Upcoming Earnings
News Coverage
GANX
Gain Therapeutics
1.7$10.50+4.8%$118.98 millionN/A0.00Gap Up
LGVN
Longeveron
0.3$5.59+2.7%$105.97 millionN/A0.00
UPC
Universe Pharmaceuticals
0.0$3.19+0.0%$69.38 millionN/A0.00Quiet Period Expiration
VRDN
Viridian Therapeutics
1.7$17.53+1.0%$68.51 millionN/A0.00Earnings Announcement
News Coverage
This page was last updated on 5/9/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.